The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to boost its domestic manufacturing and research ...

Businesses that are solid enough to perform well over extended periods, while consistently raising their payouts, are precisely what income investors should gravitate toward. Here are two corporations ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Shares of Gilead Sciences Inc. GILD shed 1.27% to $96.91 Friday, on what proved to be an all-around dismal trading session ...